Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC

Virchows Archiv

Volumn 465, Issue 2, 2014, Pages 155-163

  Steinestel, Konrad ^a,b   Lennerz, Jochen K ^c   Eder, Stefan ^a   Kraft, Klaus ^b   Arndt, Annette ^b  

^a Bundeswehr Institute of Radiobiology   (Germany)

^b Institute of Pathology and Molecular Pathology Bundeswehrkrankenhaus Ulm   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

BRAF; Colorectal carcinoma; Growth patterns; KRAS; Mismatch repair proteins; Tumor cell budding

Indexed keywords

AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CLUSTER ANALYSIS; CODON; COLORECTAL NEOPLASMS; DNA REPAIR; DNA REPAIR ENZYMES; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES;

EID: 84905992413     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1604-8     Document Type: Article

References (44)

1. Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, Mangone L, Francisci S (2012) Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer 131(7):1649-1658. doi:10.1002/ijc.26192
2. Jass JR, Love SB, Northover JM (1987) A new prognostic classification of rectal cancer. Lancet 1(8545):1303-1306 (Pubitemid 17072200)
3. Jass JR, Ajioka Y, Allen JP, Chan YF, Cohen RJ, Nixon JM, Radojkovic M, Restall AP, Stables SR, Zwi LJ (1996) Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28(6):543-548
4. Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, Wolf P, Chenard-Neu MP, Jaeck D (2001) Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 182(1):81-88 (Pubitemid 32787119)
5. Yano H, Saito Y, Kirihara Y, Takashima J (2006) Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma. Dis Colon Rectum 49(12):1867-1877. doi:10.1007/s10350-006-0733-9 (Pubitemid 44853444)
6. Garcia-Solano J, Conesa-Zamora P, Trujillo-Santos J, Makinen MJ, Perez-Guillermo M (2011) Tumour budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma. Histopathology 59(6):1046-1056. doi:10.1111/j.1365-2559.2011.04043.x
7. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M (1989) An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 63(3):539-543 (Pubitemid 19038471)
8. Hase K, Shatney C, Johnson D, Trollope M, Vierra M (1993) Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 36(7):627-635 (Pubitemid 23206317)
9. Zlobec I, Lugli A (2010) Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 1(7):651-661
10. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC (2002) Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40(2):127-132 (Pubitemid 34122114)
11. Zlobec I, Lugli A (2009) Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol 15(47):5898-5906
12. Arnold D, Seufferlein T (2010) Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 59(6):838-858. doi:10.1136/gut.2009.196006
13. Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, Novakovic S, Ocvirk J (2011) Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol 45(4):285-291. doi:10.2478/v10019-011-0039-y
14. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104(5):856-862. doi:10.1038/bjc.2011.19
15. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL (2012) Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18(23):6531-6541. doi:10.1158/1078-0432. CCR-12-0605
16. Adackapara CA, Sholl LM, Barletta JA, Hornick JL (2013) Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 63(2):187-193. doi:10.1111/his.12154
17. de la Chapelle A (2003) Microsatellite instability. N Engl J Med 349(3):209-210. doi:10.1056/NEJMp038099
18. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23(3):609-618. doi:10.1200/JCO.2005.01.086 (Pubitemid 46224239)
19. Makrodouli E, Oikonomou E, Koc M, Andera L, Sasazuki T, Shirasawa S, Pintzas A (2011) BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer 10:118. doi:10.1186/1476-4598-10-118
20. Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M (2012) Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene. doi:10.1038/onc.2012.402
21. Wang Z, Ali S, Banerjee S, Bao B, Li Y, Azmi AS, Korc M, Sarkar FH (2013) Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol 228(3):556-562. doi:10.1002/jcp.24162
22. Steinestel K, Bruderlein S, Steinestel J, Markl B, Schwerer MJ, Arndt A, Kraft K, Propper C, Moller P (2012) Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis. PLoS One 7(7):e40671. doi:10.1371/journal.pone.0040671
23. Gunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, Robert M, Kenney B (2013) KRAS mutations are associated with specific morphologic features in colon cancer. J Clin Gastroenterol 47(6):509-514. doi:10.1097/MCG.0b013e3182703030
24. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A (2010) Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 127(2):367-380. doi:10.1002/ijc.25042
25. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S (2012) Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 19(6):1944-1953. doi:10.1245/s10434-011-2174-5
26. Er TK, Chen CC, Bujanda L, Herreros-Villanueva M (2013) Clinical relevance of KRAS mutations in codon 13: where are we? Cancer Lett. doi:10.1016/j.canlet.2013.09.012
27. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J (2013) Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31(6):759-765. doi:10.1200/JCO.2012. 45.1492
28. Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A (2012) The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology 61(5):777-787. doi:10.1111/j.1365-2559.2012. 04273.x
29. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B (2012) BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 36(5):744-752. doi:10.1097/PAS.0b013e31824430d7
30. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R (2012) Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol 25(10):1315-1325
31. Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, Castagnola P, Giaretti W (2006) KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Cell Oncol 28(4):161-166 (Pubitemid 44427399)
32. Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer 50(5):307-312. doi:10.1002/gcc.20854
33. Kloor M, Michel S, von Knebel Doeberitz M (2010) Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 127(5):1001-1010. doi:10.1002/ijc.25283
34. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR (2012) Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab: NCCTG N0147. In: J Clin Oncol (Meeting Abstracts) p 3514
35. Betge J, Pollheimer MJ, Lindtner RA, Kornprat P, Schlemmer A, Rehak P, Vieth M, Hoefler G, Langner C (2012) Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 118(3):628-638. doi:10.1002/cncr.26310
36. Kojima M, Shimazaki H, Iwaya K, Kage M, Akiba J, Ohkura Y, Horiguchi S, Shomori K, Kushima R, Ajioka Y, Nomura S, Ochiai A (2013) Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer: a framework for developing an objective pathological diagnostic system using the Delphi method, from the Pathology Working Group of the Japanese Society for Cancer of the Colon and Rectum. J Clin Pathol 66(7):551-558. doi:10.1136/jclinpath-2012-201076
37. Yamauchi H, Togashi K, Kawamura YJ, Horie H, Sasaki J, Tsujinaka S, Yasuda Y, Konishi F (2008) Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today 38(10):905-910
38. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN (2006) Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol 101(12):2818-2825 (Pubitemid 44902656)
39. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB (2012) Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 49(3):151-157. doi:10.1136/jmedgenet-2011-100714
40. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5:2. doi:10.1186/1476-4598-5-2
41. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S (2010) Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222(4):350-366. doi:10.1002/path.2774
42. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28(3):466-474
43. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from Intergroup Trial CALGB 89803. Clin Cancer Res 18(3):890-900. doi:10.1158/1078-0432.ccr-11-2246
44. Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi M (2013) Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer 13(1):439